Clinical Trials Directory

Trials / Unknown

UnknownNCT04544878

Pediatric Intensive Care and COVID-19

Clinical and Biological Characteristics of Critically Ill Patients With COVID-19 Admitted to Pediatric Intensive Care Unit

Status
Unknown
Phase
Study type
Observational
Enrollment
100 (estimated)
Sponsor
Bicetre Hospital · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

In this prospective longitudinal cohort the investigators reported the clinical, and biological characteristics of all critically ill patients admitted in the pediatric intensive care unit (PICU) of Bicêtre Hospital during the 2019 coronavirus disease (COVID-19) pandemics. Patients were older than 37 weeks of gestational age. No upper limit was set as the unit was transiently converted into a pediatric "adult COVID-19" intensive care unit.

Detailed description

All patients will be monitored during their PICU stay. Clinical characteristics include: age, gender, co-morbidities, organ support therapies (mechanical ventilation, renal replacement therapy, extracorporeal membrane oxygenation, vasopressors), organ complications (pulmonary embolism, acute respiratory distress syndrome, renal failure, heart failure) and function, infective complications (ventilator associated pneumonia, central line associated bloodstream infection, pulmonary access, sepsis, septic shock), microbiologic and viral identification, 7-day and 28-day mortality. Biological characteristics include: * Admission workup: qualitative and quantitative Ig, ferritin, creatinine kinase, complement study (C3,C4,CH50), * Daily workup: blood cells count, arterial blood gas analysis, lactate, electrolytes, albumin, blood urea nitrogen, creatinine, hemostasis (fibrinogen, factor V, II+VII, factor X, prothrombin time, antiXa activity, activated cephalin time, D-dimer), C-reactive protein, procalcitonin. * Twice weekly workup: circulating cells phenotyping (T cell and subclass including Treg, B cell, Natural Killer cell, myeloid derived suppressor cell, neutrophils), interleukin 6. * Bone marrow analysis when indicated by attending staff.

Conditions

Timeline

Start date
2020-03-26
Primary completion
2021-06-01
Completion
2021-06-01
First posted
2020-09-10
Last updated
2020-09-10

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT04544878. Inclusion in this directory is not an endorsement.